Coya Therapeutics outlines biomarker stratification method for Phase 2/3 ALS trial
Bitget2026/10/28 12:04- Coya Therapeutics will present its ALSTARS trial biomarker stratification methodology at the Annual NEALS Meeting on October 28, 2026, in Clearwater, Florida.
- The ongoing Phase 2/3 trial evaluates COYA 302's efficacy and safety in amyotrophic lateral sclerosis against placebo.
- Participants are grouped by baseline neurofilament light chain levels to balance disease progression risk across treatment arms.
- Coya believes this approach may reduce patient variability and improve assessment of treatment effects.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Citi optimistic about international oil companies: low-cost resource reserves being rebuilt may drive energy sector to reverse a decade-long valuation discount
With oil prices in the mid-$70s range, Citi believes that global international oil companies (IOCs) can deliver a free cash flow yield of 7% to 8%, and achieve a real growth rate of 4% to 5% over a period of time.
Honda Motor (HMC.US) Reports 65.7% Increase in Net Profit in the First Half, Plans to Expand Production Capacity in North America and Brazil
Honda Motor (HMC.US) released its financial results for the first half of fiscal year 2027 on November 10.
Crypto winter not over? Mining rig hosting provider Bitari cancels orders at the last minute, IPO plans put on hold
Bitcoin mining service provider Bitari has withdrawn its Nasdaq IPO plan. The company originally intended to issue 4.3 million shares at $7 per share to raise $30 million. Its annual revenue is approximately $11 million.
Crypto prices
More
